Aptamer Group
Aptamer Group is a leading provider of Optimer® binders for use in therapeutics, diagnostics, bioprocessing and research. The Company strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer® technology.
Latest Content
Product News
Aptamer Group Identifies Novel Target To Enable Cell-Specific Gene Therapy for Liver Fibrosis
Aptamer validates targeted RNA delivery to liver fibrosis cells using its Optimer platform and a novel HSC marker.
Product News
Aptamer Announces New Data at ASGCT
Aptamer Group presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis, showing its potential for broad applicability in fibrotic diseases at the ASGCT 2025 Annual Meeting.
Product News
Optimer Licensing Agreements and Repeat Custom
Aptamer Group has secured two new development contracts and a licensing agreement to expand its Optimer platform’s applications in enzyme modulation and small molecule recognition.
Product News
Aptamer Group and Neuro-Bio Advance Alzheimer’s Test and Agree Royalties
Aptamer Group plc is pleased to announce the successful adaptation of the Optimer-based test for Alzheimer’s disease into an Enzyme-Linked Immunosorbent Assay (ELISA).
Product News
Licensing Agreed for Optimer As Novel Vaccine Adjuvant
Aptamer licenses Optimers to the University of Glasgow for use in swine vaccines, targeting global animal health markets.
Product News
New Optimer Contract To Develop Bioanalytical Tools for RNA Therapy
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces the signing of a new development contract with a rare disease biopharmaceutical company.
Product News
New Scientific Advisory Board Members
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce three new members to its Scientific Advisory Board (SAB).
Product News
Aptamer Extends Agreement With Genetic Medicines Customer
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders, is pleased to announce that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery vehicles.
Product News
Partnership With Microsaic Systems for Optimer-Enabled Water Monitoring
New binders will be developed to multiple waterborne pathogens. Optimer will support continuous water monitoring for rapid detection.
Product News
Aptamer and Timser Partner To Deliver World’s First Blood Test for Cervical Cancer
Optimer binders will be developed for use in a cervical cancer blood test. Agreement for up to £465,000 signed for Optimer development.
Advertisement
